Safety and efficacy comparison : ARTEMIS and PALISADE phase 3 studies of AR101 in peanut allergy

Revue Francaise d'Allergologie - Tập 61 - Trang 339-340 - 2021
A. Deschildre1, E.R. Sher2, J.O.B. Hourihane3, W.W. Carr4, K. Beyer5, N.M. Griffin6, A. Vereda7, D. Norval7, G.R. Toit8, D.C. Adelman6,9, E.H. Kim10
1Hôpital Saint-Vincent, Saint Antoine, Lille, France
2Allergy Partners of NJ, Atlantic Research Center, Ocean, NJ, USA
3RCSI Paediatrics Royal College of Surgeons in Ireland, Dublin, Ireland
4Allergy & Asthma Associates of Southern California, Food Allergy Center of Southern California, Mission Viejo, CA, USA
5Charité – Universitätsmedizin Berlin, Berlin, Germany
6Aimmune Therapeutics, Brisbane, CA, USA
7Aimmune Therapeutics, London, UK
8Guy’s and St Thomas’ NHS Foundation Trust, London, UK
9University of California, San Francisco San Francisco, CA, USA
10University of North Carolina School of Medicine, Chapel Hill, NC, USA

Thông tin
Thông tin xuất bản

Revue Francaise d'Allergologie

Tập 61

339-340

Thông tin tác giả